Printer Friendly

CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING BREAST CANCER

 CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING BREAST CANCER
 PRINCETON, N.J., Jan. 7 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) reported the initiation of Phase I human clinical trials for OncoTc(TM) BR380, the company's breast cancer imaging product.
 Breast cancer is the leading cancer in the United States according to the American Cancer Society. One out of every nine women will develop breast cancer and the rate of incidence has increased 3 percent a year for the last 10 years. An estimated 175,000 new cases of breast cancer will occur in the United States in 1991 and nearly 45,000 people will die from this disease.
 The OncoTc agent employs a MAb fragment which the company said it anticipates will seek out and bind to diseased cells. Attached to the fragment is the radioisotope technetium-99m, which following injection, is expected to reveal the extent and location of disease when a patient is scanned with a gamma camera. Cytogen said it believes that the MAb fragment is preferable to whole MAbs for imaging breast cancer because the OncoTc conjugate should clear quickly from the background blood pool areas, providing a sharper image of both primary tumors and diseased lymph nodes. Technetium-99 is the isotope chosen for this application because its half-life compares favorably to that of an antibody fragment.
 Cytogen Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies in order to optimize the function of the antibody as a delivery vehicle. The first of Cytogen Corporation's cancer imaging products has already been approved for sale in five European countries. The company currently has six cancer imaging agents under development and two of these imaging agents, for colorectal and ovarian cancer are awaiting FDA marketing approval. Two cancer therapy agents are also under development.
 /delval/
 -0- 1/7/92
 /CONTACT: Laura M. Hahn of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation ST: New Jersey IN: MTC SU:


MP -- PH002 -- 7181 01/07/92 08:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1992
Words:334
Previous Article:ALPHA-BETA TECHNOLOGY BEGINS BETAFECTIN PHASE I CLINICAL TRIALS; FIRST OF NEW ENGINEERED CARBOHYDRATE PHARMACEUTICALS TO ENTER HUMAN STUDIES
Next Article:HO-LEE-CHOW INKS MILLION-DOLLAR TRADEMARK DEAL
Topics:


Related Articles
CYTOGEN ISSUES CANCER THERAPY PHASE I RESULTS UPDATE
CYTOGEN AND CETUS ANNOUNCE DENMARK APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING NON-SMALL CELL LUNG CANCER
CYTOGEN INITIATES CLINICAL TRIALS OF THROMBOSCAN(TM), THE WORLD'S FIRST MRU PRODUCT
CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
CYTOGEN ANNOUNCES REVISION OF STRATEGIC PLAN
CYTOGEN AND CYTORAD REPORT FAVORABLE RESULTS IN PROSTATE CANCER IMAGING
CYTOGEN INITIATES CLINICAL TRIALS FOR BREAST CANCER
CYTOGEN CORPORATION ANNOUNCES UPDATE ON SECOND QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
CYTOGEN: FDA APPROVES ONCOSCINT(TM) CR/OV FOR REPEAT ADMINISTRATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters